Skip to main content
Home
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
      • Specialties
        • Vaccines & Infectious Diseases
        • Ophthalmology
        • Clinical Neuroscience
        • Rare Disease
        • Cell & Gene Therapy
        • Government
      • Additional Specialties
        • Hematology
        • Oncology
        • Maternal & Child Health
        • Medical Devices
      • Clinical Services
        • Biostatistics
        • Clinical Data Management
        • Clinical Research Services
        • Clinical Trial Management
        • Global Regulatory Affairs
        • Pharmacovigilance & Medical Monitoring
    • Veridix - Tech & AI
      • eClinical Platform
        • EDC
        • Decentralized Clinical Trials
        • Health Navigator
        • RTSM
        • eCOA / ePRO
      • AI Agents
        • Biostats and Analysis Agent
        • Data Management Agent
        • Document Authoring
      • GlobalTrace
      • Analytics & Reporting
        • Clinical Pipelines
        • VERA
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Contact Us
    • Locations

Breadcrumb

  1. Emmes Group

Safety and Immunogenicity of a Subvirion Monovalent Unadjuvanted Inactivated Influenza A(H3N2) Variant Vaccine in Healthy Persons ≥18 Years Old.

Go back to Resources

Safety and Immunogenicity of a Subvirion Monovalent Unadjuvanted Inactivated Influenza A(H3N2) Variant Vaccine in Healthy Persons ≥18 Years Old.

Authors:

Secondary:

Volume:

Pagination:

Issue:

PMID:

DOI:

Keywords:

Abstract:

Go back to Resources

Safety and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine Candidate in Flavivirus-Naive Adults: A Randomized, Double-Blinded Phase 1 Clinical Trial.

Go back to Resources

Safety and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine Candidate in Flavivirus-Naive Adults: A Randomized, Double-Blinded Phase 1 Clinical Trial.

Authors:

Secondary:

Volume:

Pagination:

Issue:

PMID:

DOI:

Keywords:

Abstract:

Go back to Resources

Progression of Vision Loss in Macular Telangiectasia Type 2.

Go back to Resources

Progression of Vision Loss in Macular Telangiectasia Type 2.

Authors:

Secondary:

Volume:

Pagination:

Issue:

PMID:

DOI:

Keywords:

Abstract:

Go back to Resources

Perfluorochemicals and human semen quality: the LIFE study.

Go back to Resources

Perfluorochemicals and human semen quality: the LIFE study.

Authors:

Secondary:

Volume:

Pagination:

Issue:

PMID:

DOI:

Keywords:

Abstract:

Go back to Resources

NIDA Clinical Trials Network Common Data Elements Initiative: Advancing Big-Data Addictive-Disorders Research.

Go back to Resources

NIDA Clinical Trials Network Common Data Elements Initiative: Advancing Big-Data Addictive-Disorders Research.

Authors:

Secondary:

Volume:

Pagination:

PMID:

DOI:

Go back to Resources

Ebola in the United States.

Go back to Resources

Ebola in the United States.

Authors:

Secondary:

Volume:

Pagination:

Issue:

PMID:

DOI:

Keywords:

Abstract:

Go back to Resources

DNA priming for seasonal influenza vaccine: a phase 1b double-blind randomized clinical trial.

Go back to Resources

DNA priming for seasonal influenza vaccine: a phase 1b double-blind randomized clinical trial.

Authors:

Secondary:

Volume:

Pagination:

Issue:

PMID:

DOI:

Keywords:

Abstract:

Go back to Resources

Component-resolved analysis of IgA, IgE, and IgG4 during egg OIT identifies markers associated with sustained unresponsiveness.

Go back to Resources

Component-resolved analysis of IgA, IgE, and IgG4 during egg OIT identifies markers associated with sustained unresponsiveness.

Authors:

Secondary:

Volume:

Pagination:

Issue:

PMID:

DOI:

Keywords:

Abstract:

Go back to Resources

Sublingual immunotherapy for peanut allergy: Long-term follow-up of a randomized multicenter trial.

Go back to Resources

Sublingual immunotherapy for peanut allergy: Long-term follow-up of a randomized multicenter trial.

Authors:

Secondary:

Volume:

Pagination:

Issue:

PMID:

DOI:

Keywords:

Abstract:

Go back to Resources

Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations.

Go back to Resources

Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations.

Authors:

Secondary:

Volume:

Pagination:

Issue:

PMID:

DOI:

Keywords:

Abstract:

Go back to Resources

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 77
  • Page 78
  • Page 79
  • Page 80
  • Current page 81
  • Page 82
  • Page 83
  • Page 84
  • Page 85
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to
Emmes Group

Delivering Global Health
Impact Through People,
Science and Technology

Main navigation
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
    • Veridix - Tech & AI
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Contact Us
    • Locations
linkedin X

Copyright ©, The Emmes Company, LLC

Footer
  • Cookie Policy
  • External Privacy Notice
  • FCOI
  • Emmes EU-U.S. Data Privacy Framework
  • Purchasing Terms and Conditions
  • Terms of Use
  • ISO Certification